2024/7/24 该公司公布和辉瑞合作开发血友病基因药物三期达标,股价暴涨,后续可期!查看全文
产业链观察07-24 21:24
#药闻简讯# 2024 年 7 月 24 日,$辉瑞(PFE)$ 今天宣布了评估giroctocogene fitelparvovec的3期研究(NCT04370054)的积极顶线结果,该研究是一种用于治疗中度至重度血友病A成人的研究性基因疗法。$Sangamo Therapeutics(SGMO)$查看全文
Sangamo Therapeutics(SGMO)2023-11-04 04:05
$Sangamo Therapeutics(SGMO)$ 8-K Current report, item 8.01 Accession Number: 0001628280-23-036697 Act: 34 Size: 1 MB 网页链接查看全文
Sangamo Therapeutics(SGMO)2023-08-09 04:55
$Sangamo Therapeutics(SGMO)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-23-206301 Act: 33 Size: 73 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2023-08-30 04:25
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-047586 Size: 6 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2023-08-30 04:25
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-047590 Size: 6 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)01-25 05:45
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-001756 Size: 6 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)01-25 05:45
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-001754 Size: 6 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)01-25 05:45
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-001755 Size: 6 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)04-20 04:25
$Sangamo Therapeutics(SGMO)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-102893 Act: 34 Size: 17 MB 网页链接查看全文
chuminhua2020-04-23 17:18
4月22日,基因治疗公司Sangamo Therapeutics$Sangamo Therapeutics(SGMO)$ 与Mogrify达成一项独家许可协议,以结合Mogrify专有的诱导多能干细胞(iPSC)和胚胎干细胞(ESC)以及Sangamo基因编辑的黄金手指-锌指蛋白(ZFP)来开发同种异体的CAR-Treg细胞疗法。根据该协议条款,Mogrify将负责从iPSC...查看全文
chuminhua2020-04-11 20:05
4月9日,基因组医学公司Sangamo Therapeutics,Inc.$Sangamo Therapeutics(SGMO)$ 宣布,已将先前宣布的股份出售给Biogen Inc.$Biogen制药(BIIB)$ ,并宣布与Biogen达成全球许可合作协议,以进行开发和商业化目前有效阿尔茨海默氏症(ST-501),帕金森氏症(ST-502),神经肌肉疾病和其他神经系统...查看全文
产业链观察2020-04-09 20:13
$Sangamo Therapeutics(SGMO)$ 宣布与$Biogen制药(BIIB)$ 达成全球合作协议,以开发和商业化阿尔茨海默氏症,帕金森氏症,神经肌肉疾病和其他神经系统疾病的基因调节疗法.@chuminhua查看全文
Grando2020-03-14 15:21
$Sangamo Therapeutics(SGMO)$ 差不多快净现金了,这两年没有融资需求,可以买点了。毕竟基因治疗,基因体外编辑,基因体内编辑这么多点,有一点突破就行了。查看全文
医药魔方2020-02-29 11:38
2月27日, Biogen与Sangamo宣布双方达成一项全球独家合作协议。Biogen获得后者ST-501(开发用于治疗包括阿尔茨海默病在内的Tau蛋白病变)、ST-502(开发用于治疗包括帕金森病在内的突触核蛋白病)和一个未披露靶点的神经肌肉疾病项目的全球独家权利。
此外,Biogen在未来5年还拥有独家选择权利...查看全文
chuminhua2020-02-28 23:13
2/27,虽然Biogen$Biogen制药(BIIB)$ “复活”的阿尔兹海默症药物aducanumab前途还未知,但该公司达成协议,与基因编辑公司Sangamo Therapeutics$Sangamo Therapeutics(SGMO)$ 合作,共同开发相关疾病。Sangamo 将收到2.5亿美元现金和股票的前期款,23.7亿美元里程金,以及未来的销售提成。Biogen...查看全文
JZee2020-02-28 05:21
$Sangamo Therapeutics(SGMO)$ 和$Biogen制药(BIIB)$ 达成合作协议,按照9.21元向biogen发售2千4百万股,并获得1.25亿美元授权费,未来合作完成各个里程碑还可能获得23.7亿美元。锌手指技术还能榨出点价值查看全文
智通财经APP获悉,近期,RBC针对Verrica Pharmaceuticals(VRCA.US)、Sangamo Therapeutics(SGMO.US)、GooseHead Insurance(GSHD.US)三家公司发表研报,并强调了这三只股票未来强劲的长期增长前景,预计在未来一年的上行空间将至少达到50... 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, item 8.01 Accession Number: 0001628280-24-032815 Act: 34 Size: 287 KB 网页链接
$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001086364-24-008122 Act: 34 Size: 12 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016686 Size: 6 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015752 Size: 8 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015753 Size: 7 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015754 Size: 7 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015755 Size: 8 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 5.02, 5.03, 5.07, and 9.01 Accession Number: 0001628280-24-026903 Act: 34 Size: 13 MB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014796 Size: 9 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-014798 Size: 9 KB 网页链接